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ABSTRACT: Metallo-β-lactamases (MBLs) are a growing
threat to the use of almost all clinically used β-lactam
antibiotics. The identiﬁcation of broad-spectrum MBL
inhibitors is hampered by the lack of a suitable screening
platform, consisting of appropriate substrates and a set of
clinically relevant MBLs. We report procedures for the
preparation of a set of clinically relevant metallo-β-lactamases
(i.e., NDM-1 (New Delhi MBL), IMP-1 (Imipenemase), SPM-
1 (Saõ Paulo MBL), and VIM-2 (Verona integron-encoded
MBL)) and the identiﬁcation of suitable ﬂuorogenic substrates
(umbelliferone-derived cephalosporins). The ﬂuorogenic sub-
strates were compared to chromogenic substrates (CENTA,
nitroceﬁn, and imipenem), showing improved sensitivity and
kinetic parameters. The eﬃciency of the ﬂuorogenic substrates was exempliﬁed by inhibitor screening, identifying 4-
chloroisoquinolinols as potential pan MBL inhibitors.
■ INTRODUCTION
Selection pressure caused by frequent use of β-lactam
antibiotics, including penicillins, cephalosporins, carbapenems,
and monobactams, has resulted in the emergence and
dissemination of highly eﬃcient resistance mechanisms in
clinically relevant bacterial pathogens. This rapid adaptation of
bacterial strains to commonly used antibiotics is an increasing
global threat to public health care.1,2 An important mechanism
of resistance to β-lactam antibiotics, including clinically
challenging Gram-negative organisms, involves β-lactamase
catalysis. β-Lactamases can be classiﬁed into those employing
a nucleophilic serinyl residue at their active site (serine-β-
lactamases, SBLs, classes A, C, and D) and those employing
one or two zinc ions to promote hydrolysis (metallo-β-
lactamases, MBLs, class B).3 The combination of a penicillin
antibiotic and an SBL inhibitor has substantially extended the
utility of the former, as, for example, in the case of amoxicillin
and clavulanic acid (Augmentin).4 In addition to clavulanic
acid, two other class A (penicillinase) β-lactamase inhibitors are
used, tazobactam and sulbactam; all three inhibitors are
themselves β-lactams, though in contrast to penicillins they
react with SBLs to form relatively stable acyl-enzyme
complexes.5 These SBL inhibitors, however, appear to have
no eﬀect on MBLs.6 β-Lactam antibiotics have been developed
that possess resistance to SBLs, or as in the case of
carbapenems, they have been developed to be inhibitors or
relatively poor substrates.7 However, since the pioneering
introduction of the SBL-targeting inhibitors, progress in the
development of clinically useful, β-lactamase-speciﬁc inhibitors
has been limited. In the case of SBLs, at least one compound,
Avibactam, is currently in clinical trials as a combined class A
and class C SBL inhibitor.8
MBLs, which, unlike the SBLs, are not structurally or
mechanistically related to the penicillin-binding proteins
(PBPs), were ﬁrst identiﬁed approximately 50 years ago.9
However, as a result of their apparently restricted distribution
to the chromosomes of less pathogenic species, they were long
not considered to represent a signiﬁcant threat to the clinical
eﬀectiveness of β-lactams. The emergence of horizontally
acquired MBLs, where horizontal gene transfer permits genetic
material to be transferred between individual bacteria of the
same species or between diﬀerent species, has led to their
extensive dissemination across geographical and species
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boundaries and now threatens the eﬀectiveness of almost all β-
lactams, including carbapenems (i.e., “last resort” antibiotics);10
the monobactam aztreonam is a current exception. MBLs
identiﬁed on transferrable plasmids (e.g., the NDM-, IMP-,
VIM-, GIM-, and SPM-type enzymes) are considered a
prevalent and immediate clinical problem.11 Various structur-
ally diverse types of MBL inhibitors have been described,
including carboxylic/succinic acids,12 triazoles/tetrazoles,13
thiols,14 triﬂuoromethyl ketones,15 and others.16 To date, no
clinically useful MBL inhibitor has been reported. This, in part,
may reﬂect the technical and scientiﬁc challenges in the
development of an MBL−β-lactam-based combination therapy.
There is also extensive structural diversity in the MBL family,
particularly in the proposed mobile loop regions around the
active site.17 For an MBL inhibitor to be clinically useful, it is
possible that more than one MBL will need to be inhibited. In
an eﬀort to help enable work that will lead to the development
of useful MBL inhibitors, we here describe an assay platform for
clinically relevant MBLs, including protein production
procedures and assay conditions using both chromogenic and
ﬂuorogenic substrates.
■ RESULTS AND DISCUSSION
Several screening methods for the in vitro and in vivo detection
of β-lactamases have been reported.18 Representative substrates
currently in use for β-lactamases include chromogenic
cephalosporin-based substrates, such as CENTA,19 PADAC,20
and nitroceﬁn,21 cephalosporin-based ﬂuorogenic substrates,22
bioluminescent probes,23 and ﬂuorescence resonance energy
transfer (FRET)-based substrates.24 These substrates have
mainly been applied in research centered around SBLs and only
in one case on MBLs (L1 and CcrA).22c The large-scale
application of these type of compounds in automated high-
throughput screening (HTS) for MBL inhibitors is, however,
hampered by their lengthy and often diﬃcult synthesis and the
high costs associated with these substrates. More importantly,
these substrates suﬀer from poor substrate recognition by some
MBLs as a result of the high diversity of this enzyme family
whose members vary signiﬁcantly in sequence, structure, and
substrate speciﬁcity, thus making it hard to use a single
substrate for broad MBL activity screening. The development
of new assays for broad-range MBL activity screening, based on
hydrolysis of chromogenic or ﬂuorogenic β-lactams, would,
however, signiﬁcantly facilitate inhibitor identiﬁcation. Not
unimportantly, large-scale inhibitor screening against diﬀerent
MBLs needs an inexpensive substrate, thus requiring a simple,
scalable, and cost-eﬃcient synthetic route. To develop assay
procedures suitable for a range of MBLs, we targeted four
clinically relevant enzymes as well as the MBL from Bacillus
cereus (BcII), which has been extensively used as a model
enzyme. The clinically relevant enzymes chosen were NDM-1
(New Delhi MBL), IMP-1 (Imipenemase), SPM-1 (Saõ Paulo
MBL), and VIM-2 (Verona integron-encoded MBL). To
identify MBL substrates useful for eﬃcient inhibitor screening,
we prepared and tested substrates on the above-mentioned
panel of MBLs. These substrates included three chromogenic
substrates, i.e., imipenem, nitroceﬁn, and CENTA, and ﬁve
coumarin-linked substrates, i.e., FC1−FC5 (Figure 1).
Fluorescent substrates FC1 and FC2 release 7-mercapto-4-
methylcoumarin upon hydrolysis, resulting in a decrease of
ﬂuorescence. Conversely, ﬂuorogenic substrates FC3−FC5
liberate 7-hydroxycoumarin upon hydrolysis of the lactam
ring, producing an increased ﬂuorescence signal (Figure 2).
Protein Production. Details are provided in the Supporting
Information. For the production of recombinant BcII, IMP-1,
and NDM-1 MBLs in Escherichia coli, vectors that have been
previously described were used, i.e., the pET9a-BcII, pET-26b
IMP-1, and pOPINF NDM-1 plasmids.25 In the case of the
MBLs VIM-2 and SPM-1, new pTriEx-based pOPINF vectors
were constructed.26 These vectors encode the mature VIM-2
Figure 1. Substrates for metallo-β-lactamase activity measurements.
Figure 2. Hydrolysis of substrates by MBLs, resulting in either an increase or a decrease of ﬂuorescence.
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and SPM-1 sequences (i.e., with the periplasmic export
sequences removed) fused to N-terminal hexahistidine tags,
cleavable with 3C protease. The VIM-2 and SPM-1 genes were
codon optimized for E. coli (Genscript, Piscataway, NJ) and
inserted into the pOPINF vector. All the MBLs were produced
using in-house-constructed E. coli BL21(DE3) pLyS cells,
which were grown in 2TY medium. For the protein
puriﬁcations standard procedures were used. The purity of
the MBL proteins was determined to be >95% by SDS−PAGE
analysis (see the Supporting Information, Figure SI_4).
Scheme 1. Synthesis of FC1-5: (A) Thiacoumarin Cephalosporin, (B) Hydroxylcoumarin Cephalosporinsa
aReagents and conditions: (a) MMC, DiPEA, DMF, rt, 2 h; (b) TFA/anisole (5:1), 0 °C, 30 min; (c) mCPBA (1 equiv), CH2Cl2, 0 °C, 1 h; (d) NaI
(10 equiv), acetone, rt, 2 h, (e) 7-HC, K2CO3, MeCN, rt, 4 h; (f) mCPBA (2 equiv), CH2Cl2, 0 °C, 3 h.
Table 1. Kinetic Data for Chromogenic and Fluorogenic Substrates on MBLs
literature data
entry enzyme substrate [E]a (pM) KM (μM) kcat (s
−1) kcat/KM (μM
−1·s−1) kcat/KM (μM
−1·s−1) ref
1 NDM-1 nitroceﬁn 1000 8.8 ± 1.1 25.3 2.9 4.1 33
2 CENTA 1000 34.6 ± 6.6 92.5 2.7 NDb ND
3 imipenem 250 111.2 ± 11.7 398.5 3.6 0.5 33
4 FC3 50 17.6 ± 1.7 102.6 5.8
5 FC4 50 4.0 ± 0.8 125.7 32.0
6 FC5 50 2.4 ± 0.2 298 124.1
7 VIM-2 nitroceﬁn 100 7.2 ± 0.6 225.6 31.2 42.7 34
8 CENTA 1000 26.1 ± 3.1 48.2 1.8 ND ND
9 imipenem 1000 37.8 ± 11.5 41.6 1.1 3.8 34
10 FC4 50 6.3 ± 0.4 125.5 20.0
11 FC5 100 15.2 ± 1.2 291.2 19.1
12 IMP-1 nitroceﬁn 50 55.7 ± 4.8 2794 50.2 2.3 35
13 CENTA 100 17.1 ± 2.0 431.9 25.3 2.0 27
14 imipenem 50 42.7 ± 6.7 1200 28.1 1.2 35
15 FC4 1 15.2 ± 0.7 12200 807
16 FC5 5 16.8 ± 1.9 8706 517
17 SPM-1 nitroceﬁn 50 × 103 16.0 ± 3.7c 0.7 0.04 0.12 36
18 CENTA 10 × 103 25.3 ± 6.1 6.1 0.2 ND ND
19 imipenem 10 × 103 330.9 ± 35.5 37.2 0.1 1.0 36
20 FC4 500 2.5 ± 0.2 8.7 3.5
21 FC5 1000 2.7 ± 0.2 27.38 10.3
22 BcII nitroceﬁn 1000 8.1 ± 1.0 14.9 1.8 0.64 37
23 CENTA 1000 135.9 ± 16.4 8.9 0.06 0.15 27
24 imipenem 1000 >1000 583 0.4 0.13 38
25 FC4 1000 24.4 ± 1.7 17.1 0.7
26 FC5 1000 40.4 ± 3.3 151.1 3.7
aThe enzyme concentrations of the puriﬁed proteins were determined using a NanoDrop spectrometer; concentrations of diluted solutions used in
the assay were calculated from the original concentration. bND = not determined. cThe following apparent Ki value for substrate/product inhibition
was determined: 36.6 ± 15.2.
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Synthesis of Substrates. CENTA was prepared using a
modiﬁed literature procedure.27 Cleavage of 5,5-dithiobis(2-
nitrobenzoic acid) by dithiothreitol (DTT) yielded 3-carboxyl-
4-nitrothiophenol, which was subsequently used to convert
commercially available cephalothin into CENTA by heating (65
°C, 3 h). Use of chromatographically puriﬁed 3-carboxyl-4-
nitrothiophenol gave CENTA in high purity and satisfactory
yield after a single acid/base extraction.28
Fluorogenic cephalosporin 1 (FC1) was prepared from
commercially available p-methoxybenzyl (PMB) ester-pro-
tected chlorocephalosporin (CC) via substitution with 7-
mercapto-4-methylcoumarin (MMC), followed by acid-medi-
ated PMB deprotection (Scheme 1A). Treatment of CC with
MMC resulted in the formation of both the Δ2- and Δ3-alkene
isomers of compound 1. Subjecting the Δ2−Δ3 isomer mixture
to acid-mediated PMB deprotection conditions led to complete
deprotection within 1 h, generating FC1 (Δ2−Δ3 mix). To
circumvent the Δ2−Δ3 isomerization issue, oxidation of the
thiazine sulfur atom with mCPBA was performed prior to
alkylation (Scheme 1A).29 The Δ3-alkene (S)-sulfoxide 2 was
obtained in good yield (72%); subsequent alkylation with
MMC in the presence of N,N-diisopropylethylamine gave 3 as
a single isolate isomer in reasonable yield (49%). Acid-mediated
PMB deprotection yielded FC2 in good yield (88%). Notably,
MMC appears to be nonﬂuorescent in its free form, whereas
the thioether cephalosporin derivatives (i.e., 1 and 3) showed
signiﬁcant ﬂuorescence. While this was not our objective, FC2
has potential as an “inverse ﬂuorogenic” substrate (for
spectroscopic data see the Supporting Information, Figure
SI_1).
With the aim of developing a ﬂuorogenic MBL substrate, we
focused on 7-hydroxycoumarin (7-HC) cephalosporin deriva-
tives, with the knowledge that umbelliferone shows strong
ﬂuorescence in its free form while being nearly nonﬂuorescent
when ether-derivatized.30 During the course of our inves-
tigations, Rao and co-workers reported the synthesis and
application of FC3 and FC4 as SBL ﬂuorogenic substrates
(speciﬁc for BalC over TEM-1).31 Their reported procedure
(with minimal Δ2−Δ3 isomerization) for the synthesis of FC3
and FC4 proved to be eﬃcient and yielded the desired
ﬂuorogenic probes (FC3 and FC4) in satisfactory yields
(Scheme 1B). Besides substrates FC3 (sulﬁde) and FC4 ((S)-
sulfoxide), we also prepared substrate FC5 (sulfone). Treat-
ment of compound 4 with 2 equiv of mCPBA gave clean
conversion to compound 6, which upon PMB deprotection
yielded substrate FC5 in good yield.
Metallo-β-lactamase Assays. Initially time-dependent
changes in absorbance and/or emission spectra upon hydrolysis
of the potential MBL substrates were recorded to investigate
the optimal wavelengths for analysis (see the Supporting
Information, Figures SI_2 and SI_3). For the frequently used
chromogenic substrates, i.e., imipenem (carbapenem) and
nitroceﬁn and CENTA (cephalosporins), this resulted in
preferred readout absorption wavelengths of 300, 405, and
492 nm, respectively. For ﬂuorogenic substrates FC3−FC5 the
absorption and emission spectra of umbelliferon in HEPES
assay buﬀer (pH 7.5) were measured and their corresponding
optimal wavelengths applied in the ﬂuorescence-based assay
(λex = 380 nm and λem = 460 nm).
32
We then determined kinetic parameters for diﬀerent MBL−
substrate combinations. The data for the chromogenic
substrates (Table 1) are generally in good agreement with
previously reported data,27,39 with the only substantial
dissimilarity being the lower KM values obtained by us in the
case of CENTA, possibly because of increased purity of the
substrate. Direct quantitative comparison of the obtained data
with reported values is, however, diﬃcult as a result of
variations in protein production conditions, concentration of
metal ions added, etc. The improved stability of CENTA
compared to imipenem renders it an attractive substrate for
inhibitor identiﬁcation. However, MBL inhibition by the
hydrolyzed cephalosporin products (for BcII,40 CphA,41 and
Sfh-I42) or the liberated thiophenol from CENTA (for IMP-1)
could complicate interpretation of the results. Examination of
the data in Table 1 reveals the high sensitivity of the ﬂuorogenic
MBL substrates, which enable the use of enzyme concen-
trations (generally ≫1 nM) well below those used with
chromogenic substrates (generally 1−50 nM).
In the case of the combination of NDM-1 and FC3−FC5, up
to 5−20 times lower enzyme concentration was used as
compared to enzyme concentrations required for imipenem or
nitroceﬁn. Further testing of NDM-1 with the three ﬂuorogenic
substrates FC3−FC5, with diﬀerent sulfur oxidation states,
disclosed signiﬁcantly diﬀerent kcat/KM values (up to 20-fold),
implying catalytic eﬃciency is altered by the oxidation state of
the thiazine sulfur atom. We observed that the stability of FC3
in aqueous solution is substantially lower than that of FC4 and
FC5. Autohydrolysis studies in buﬀer at room temperature
showed substantial hydrolysis of FC3 after 3 h, while both FC4
and FC5 were found to be stable for at least 8 h. Solutions of
FC4 and FC5 could be used for 1−2 days when stored on ice.
Moreover, DMSO stock solutions, stored at −20 °C, could be
used several months after preparation without any detectable
decomposition. Storage of compounds FC4 and FC5 as solids
at −20 °C enabled use of these compounds over a prolonged
period of time (i.e., months). As a result, FC4 and FC5 were
tested on the other MBLs.
For nearly all the clinically important MBLs, FC4 and FC5
showed higher kcat/KM values than the chromogenic substrates
(with VIM-2 being the only exception). On analysis of the
VIM-2 results, we found that FC5 is preferred over FC4 and
performs equally well as nitroceﬁn, having similar kcat values
though slightly diﬀerent KM values (7.2 μM vs 15.2 μM,
respectively) and consequently diﬀerent kcat/KM values (31.2
μM−1·s−1 vs 19.1 μM−1·s−1).
The kinetic data of the ﬁve substrates for IMP-1 reveal that
FC4 outperforms all other substrates mainly as a result of its
high kcat value (i.e., 807 μM
−1·s−1). As depicted in Figure 2A
substrate concentrations up to 100 μM could be applied
without perturbing the measurement. Although FC4 has a low
KM compared to the other substrates tested on IMP-1, its high
sensitivity allows for accurate measurement as indicted by the
low interexperimental error (Figure 3A, experiment performed
in triplicate).43 As a result of the high sensitivity of both FC4
and FC5, a 20-fold lower IMP-1 concentration could be used
(i.e., picomolar enzyme concentration range) while retaining a
KM value in the micromolar range, thus allowing for the
detection of weak binding fragments or slow-binding
inhibitors.44
In the case of SPM-1, both FC4 and FC5 outperform all the
tested chromogenic substrates. Interestingly, we found that
SPM-1 is inhibited by nitroceﬁn/nitroceﬁn-derived species at a
concentration of 36 μM (see Figure 3B and Table 1). Although
β-lactams can act as inhibitors of MBLs, as is apparent for
nitroceﬁn and imipenem at high concentrations (e.g., nitroceﬁn
for SPM-1, this paper, and for CphA and Sfh-I, refs 45 and 42,
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respectively); the high sensitivity of the here reported
ﬂuorogenic substrates (FC4 and FC5) allows for the use of
extremely low substrate concentrations.
In Silico Studies. In an attempt to investigate the diﬀerent
substrate binding constants of nitroceﬁn, imipenem, CENTA,
and FC4 for the diﬀerent MBLs, we performed in silico docking
studies. Docking of nitroceﬁn, imipenem, CENTA, and FC4 in
IMP-1, NDM-1, and VIM-2 (PDB IDs 1JJT,12b 3Q6X,46 and
1KO3,47 respectively) was performed using AutoDock 448 and
SPROUT software.49 After analysis of the obtained unhy-
drolyzed−enzyme models (see the Supporting Information),
the diﬀerent docking poses, calculated by Autodock 4 and
SPROUT, were scored and compared to the substrate binding
constants (KM) (Table SI_1, Supporting Information). Assess-
ment of the SPROUT docking scores generally reveals a better
correlation with the kinetic parameters obtained in vitro
(speciﬁcally KM values in the cases of NDM-1 and VIM-2)
compared to the docking scores generated by Autodock 4.
However, for all three enzymes, the highest ranking substrate in
terms of the SPROUT and Autodock scores is FC4, which was
also measured to have the highest binding aﬃnity for all three
enzymes. Although in-depth structural analyses are required,
these modeling results suggest that the cephalosporins may
bind to the active site in more than one orientation, including
catalytically nonproductive ones. Overall, these results empha-
size the importance of experimentally determining optimal
MBL−substrate combinations and the need for more structural
analyses on MBL−substrate complexes.
Inhibitor Screening. To achieve clinical utility, MBL
inhibitors may need to act on more than one MBL subfamily.
This is potentially challenging because of the generally low
sequence similarity between MBLs of diﬀerent subfamilies (B1,
B2, B3). Most clinically relevant MBLs are from the B1
subfamily; however, SPM-1 presents a high similarity with both
the B1 and B2 subfamilies50 and hence was used as a starting
point for proof of principle inhibitor screening. To validate our
screening method, we screened a series of 4-chloroisoquinolinol
derivatives (7a−7g)28 against SPM-1 using FC4 as a reporter
substrate (Table 2). This set of compounds was selected as a
result of their previously reported inhibition of metal-binding
oxygenases.51 Screening for residual activity of compounds 7a−
7g, at concentrations of 200 μM and 1 mM, revealed that the 4-
chloroisoquinolinols bearing a Phe-, Tyr-, or Val-based side
chain were poor inhibitors. In contrast, the compounds
derivatized with a Trp, Leu, Asp, or Glu residue inhibited
SPM-1, with the tryptophan-functionalized chloroisoquinoli-
nols (S)-7d and (R)-7d giving the most promising results (3%
and 8% residual activity (RA) at 200 μM, respectively).
Following from the positive screening results obtained with
the SPM-1/FC4 pair, IC50 values were determined for (S)-7d
and (R)-7d against our MBL panel using FC4 and the
conditions reported in Table 1; the FC4 concentrations
correspond to the experimentally determined KM values
(Table 1). The IC50 values (Table 3) reveal that both (S)-7d
and (R)-7d are relatively weak, but broad-spectrum MBL
inhibitors with IC50 values ranging from 20 to 130 μM. Since
the inhibitor activity of these compounds is in the low
micromolar range, they may serve as good starting points for
further optimization.
To further validate our assay platform, we measured the IC50
value of the reported inhibitor L-captopril52 against NDM-1.
Measuring at the KM value of FC4 on NDM-1, we obtained an
IC50 value of 10.0 ± 1.9 μM corresponding to a Ki of 5.0 μM
for L-captopril.53 Using imipenem as the reported substrate, an
IC50 of 13.2 ± 1.5 μM corresponding to a Ki of 6.6 μM were
Figure 3. (Top) IMP-1 with FC4. (Bottom) SPM-1 with nitroceﬁn
(substrate or product inhibition). Errors are reported as standard
errors, n = 3.
Table 2. Residual Activities (RAs) on SPM-1 at 1 mM and
200 μMa,b
aFor the synthesis of compounds 7a−7g see the Supporting
Information. bThe remaining activity was measured by applying a 10
min preincubation time used in previous MBL work; see refs 18a and
44.
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determined. Thus, under the same assay conditions, we found
that the ﬂuorogenic substrate (FC4) and the chromogenic
substrate (imipenem) produced similar IC50 and Ki values.
However, our values are lower than the previously reported
IC50 and Ki values for L-captopril on NDM-1 using imipenem as
the reported substrate (202 μM54 and 39 μM,52b respectively),
possibly reﬂecting diﬀerences in assay conditions, protein
constructs, and enzyme production procedures.
■ CONCLUSIONS
The development of broad-screen MBL inhibitors has been
hampered by the lack of an appropriate, eﬃcient screening
platform for multiple MBLs. The development of such a
screening platform has been hindered by the lack of suitable
detection substrates. The results of our comparative study,
employing ﬁve substrates and ﬁve MBLs, reveal striking
diﬀerences in the kinetic parameters for diﬀerent enzyme−
substrate combinations. Fluorogenic substrates FC4 and FC5
are highly sensitive and eﬃcient substrates for the clinically
relevant MBLs, with one or both of them having kcat/KM values
of >10 μM−1·s−1. The suitability of FC4 for inhibitor screening
was demonstrated by testing a set of 4-chloroisoquinolinols as
MBL inhibitors. This work yielded two compounds ((S)-7d
and (R)-7d) that displayed inhibitory activity against our panel
of MBLs, albeit at moderate inhibition concentrations (μM);
nonetheless, the results reveal the feasibility of broad-spectrum
MBL inhibition.
■ EXPERIMENTAL SECTION
The Supporting Information contains a complete general experimental
section, including all procedures and equipment used. In general,
chemicals were purchased from commonly used suppliers (Aldrich,
Acros, Alfa Aesar, and TCI) and were used without further
puriﬁcation. (6R,7R)-4-Methoxybenzyl 3-(chloromethyl)-8-oxo-7-(2-
phenylacetamido)-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylate
(PMB-protected Cep-Cl) was obtained from Activate Scientiﬁc (Prien,
Germany).
(6R,7R)-4-Methoxybenzyl 8-Oxo-3-(((2-oxo-2H-chromen-7-
yl)oxy)methyl)-7-(2-phenylacetamido)-5-thia-1-azabicyclo-
[4.2.0]oct-2-ene-2-carboxylate (4). To a suspension of Cl-Cep-
OPMB ester (680 mg, 1.4 mmol) in acetone (10 mL) was added NaI
(2.10 g, 14.0 mmol, 10 equiv). The reaction was stirred at rt for 2 h,
after which the solvent was removed in vacuo. The crude mixture was
partitioned between H2O (10 mL) and EtOAc (10 mL), and the layers
were separated. The H2O layer was extracted with EtOAc (2 × 15
mL), after which the combined organic layers were washed with a 5%
NaS2O3 aq solution (2 × 20 mL) and brine (20 mL). The organic
layer was dried over Na2SO4, ﬁltered, and concentrated in vacuo. The
crude product was dissolved in MeCN (15 mL), and 7-
hydroxycoumarin (454 mg, 2.8 mmol, 2 equiv) and K2CO3 (4.2
mmol, 4 equiv) were added. The conversion of the reaction was
monitored by TLC analysis (cHex/EtOAc, 1:1), and completion was
reached after 4 h. The solvent was evaporated in vacuo, and the
resulting crude mixture was partitioned between H2O (10 mL) and
EtOAc (10 mL). After separation of the layers, the H2O layer was
extracted with EtOAc (2 × 15 mL), after which the combined organic
layers were washed with a 5% NaS2O3 aq solution (2 × 20 mL) and
brine (20 mL). The organic layer was dried over Na2SO4, ﬁltered, and
concentrated in vacuo. The crude product was puriﬁed by column
chromatography (cHex/EtOAc, 1:1) to yield compound 4 as a light
brown solid (392 mg, 46%). Rf = 0.30 (cHex/EtOAc, 1:1).
1H NMR
(400 MHz, DMSO-d6): δ = 9.20 (d, J = 8.0 Hz, 1H), 7.98 (d, J = 9.5
Hz, 1H), 7.59 (d, J = 8.5 Hz, 1H), 7.17 - 7.33 (m, 8H), 6.92 (d, J = 1.5
Hz, 2H), 6.87 (dd, J = 8.5, 2.5 Hz, 1H), 6.79 (d, J = 8.5 Hz, 2H), 6.30
(d, J = 9.5 Hz, 1H), 5.44 (dd, J = 7.5, 4.0 Hz, 1H), 5.11−5.19 (m, 2H),
5.01−5.10 (m, app d, 2H), 4.64−4.76 (m, app q, 2H), 3.69 (s, 3H),
3.47−3.57 (m, 2H) ppm. 13C NMR (101 MHz, DMSO-d6): δ = 170.9,
167.0, 163.8, 160.9, 160.3, 159.3, 155.2, 144.3, 135.7, 130.0 (2C),
129.5, 129.1 (2C), 128.2 (2C), 126.9, 126.5, 122.4, 118.8, 113.7 (2C),
112.9, 112.7 (2C), 101.4, 69.8, 67.2, 60.8, 55.0, 52.9, 49.7, 41.6 ppm.
LRMS: mass calcd for C33H27N2O8S (M − H) 611.15, mass found (M
− H) 611.0.
(6R,7R)-4-Methoxybenzyl 8-Oxo-3-(((2-oxo-2H-chromen-7-
yl)oxy)methyl)-7-(2-phenylacetamido)-5-thia-1-azabicyclo-
[4.2.0]oct-2-ene-2-carboxylate 5-Oxide (5). To a suspension of
compound 4 (122 mg, 0.2 mmol) in dry CH2Cl2 (5 mL) cooled to 0
°C was added mCPBA (45 mg, 0.2 mmol, 1 equiv). The reaction was
stirred at 0 °C for 30 min followed by an additional 1 h at rt (a white
precipitate was formed). The crude product was dry-loaded onto silica
and puriﬁed by column chromatography (CH2Cl2/EtOAc, 8:2) to
yield compound 5 as a cream white solid (60 mg, 48%). Rf = 0.80
(CH2Cl2/MeOH, 9:1).
1H NMR (400 MHz CDCl3): δ = 7.64 (d, J =
9.5 Hz, 1H), 7.27−7.40 (m, 8H), 6.91 (d, J = 8.5 Hz, 2H), 6.74−6.78
(m, 2H), 6.67 (d, J = 10.0 Hz, 1H), 6.30 (d, J = 9.5 Hz, 1H), 6.10 (dd,
J = 10.0, 5.0 Hz, 1H), 5.22−5.35 (m, app mix of d and q, 3H), 4.80 (d,
J = 13.5 Hz, 1H), 4.45 (dd, J = 5.0, 1.5 Hz, 1H), 3.99 (d, J = 19.0 Hz,
1H), 3.81 (s, 3H) 3.65 (m, app d, J = 5.5 Hz, 2H), 3.28 (d, J = 19.0
Hz, 1H) ppm. 13C NMR (101 MHz, DMSO-d6): δ = 171.1, 164.5,
160.7 (2C), 160.2, 159.4, 155.2, 144.3, 135.8, 130.4 (2C), 129.5, 129.1
(2C), 128.3 (2C), 126.8, 126.6, 125.0, 119.6, 113.7 (2C), 112.8, 101.6,
67.5, 67.3, 66.5, 58.4, 55.1, 45.4, 41.4 ppm. LRMS: mass calcd for
C33H27N2O9S (M − H) 627.14, mass found (M − H) 627.0.
(6R,7R)-4-Methoxybenzyl 8-Oxo-3-(((2-oxo-2H-chromen-7-
yl)oxy)methyl)-7-(2-phenylacetamido)-5-thia-1-azabicyclo-
[4.2.0]oct-2-ene-2-carboxylate 5,5-Dioxide (6). To a suspension
of compound 4 (100 mg, 0.16 mmol) in dry CH2Cl2 (10 mL) cooled
to 0 °C was added mCPBA (74 mg, 0.35 mmol, 2 equiv). The reaction
was stirred at 0 °C for 30 min (formation of sulfoxide observed), after
which the reaction was warmed to rt and stirred overnight. Upon
completion of the reaction, the crude product was dry-loaded onto
silica and puriﬁed by column chromatography (CH2Cl2/MeOH, 9:1)
to yield the desired product as a white solid (35 mg, 34%). Rf = 0.85
(CH2Cl2/MeOH, 9:1).
1H NMR (400 MHz, DMSO-d6) (small
amount of mCBA present): δ = 8.93 (d, J = 8.5 Hz, 1H), 8.01 (d, J =
9.5 Hz, 1H), 7.87−7.93 (m, 1H), 7.63 (d, J = 8.5 Hz, 1H), 7.18−7.34
(m, 7H), 6.94−6.88 (m, 2H, 2 signals overlapping), 6.81−6.86 (m,
app d, 2H), 6.33 (d, J = 9.5 Hz, 1H), 6.01 (dd, J = 8.5, 5.0 Hz, 1H),
5.43 (d, J = 4.5 Hz, 1H), 5.22 (s, 2H), 4.89−4.84 (m, app d, 2H), 4.46
(d, J = 18.5 Hz, 1H) (part of AB system), 4.23 (d, J = 18.5 Hz, 1H)
(part of AB system), 3.70 (s, 3H), 3.60 (d, J = 5.0 Hz, 2H) ppm. 13C
NMR (101 MHz, DMSO-d6): δ = 170.9, 164.5, 160.6 (2C), 160.2,
159.4, 155.2, 144.3, 135.6, 130.4 (2C), 129.5, 129.2 (2C), 128.2 (2C),
126.6, 126.5, 124.6, 124.0, 113.7 (2C), 112.9, 112.8, 101.6, 67.8, 66.8,
66.2, 58.4, 55.1, 50.9, 41.2 ppm. LRMS: mass calcd for C33H27N2O10S
(M − H) 643.14, mass found (M − H) 643.0.
(6R,7R)-8-Oxo-3-(((2-oxo-2H-chromen-7-yl)oxy)methyl)-7-(2-
phenylacetamido)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-car-
boxylic Acid 5-Oxide (FC4). Compound 5 (50 mg, 81.6 μmol) was
cooled to 0 °C prior to the addition of TFA/anisole (5:1, 3 mL). The
resulting reaction mixture was stirred at 0 °C for 30 min with constant
Table 3. IC50 Values (μM) for a Panel of Metallo-β-lactamases
a
MBL (S)-7d (R)-7d MBL (S)-7d (R)-7d
SPM-1 23.2 ± 1.1 46.6 ± 1.1 VIM-2 54.7 ± 1.4 55.3 ± 1.3
IMP-1 75.6 ± 1.5 74.1 ± 1.6 Bc II 61.3 ± 1.3 132.4 ± 1.3
NDM-1 61.4 ± 1.3 47.1 ± 1.1
aIC50 determinations were performed in duplicate over a range of 0.25−200 μM.
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monitoring of the conversion by TLC analysis (CH2Cl2/EtOAC, 8:2).
Upon completion of the reaction, cold Et2O (5 mL) was added, which
resulted in the formation of a precipitate. The solid material was
ﬁltered oﬀ, washed with Et2O (2 × 5 mL), and subsequently dried
under high vacuum to yield the desired product as an oﬀ-white solid
(15 mg, 37%). Rf = 0.10 (CH2Cl2/MeOH +AcOH, 9:1).
1H NMR
(400 MHz, DMSO-d6): δ = 8.45 (d, J = 8.5 Hz, 1H), 8.00 (d, J = 9.5
Hz, 1H), 7.65 (d, J = 8.5 Hz, 1H), 7.27−7.32 (m, 4H), 7.24 (td, J =
8.5, 4.0 Hz, 1H), 6.93−7.01 (m, 1H), 6.31 (d, J = 9.5 Hz, 1H), 5.81
(dd, J = 8.0, 4.5 Hz, 1H), 5.14 (d, J = 12.5 Hz, 1H), 4.87−4.93 (m,
1H), 3.98 (d, J = 18.0 Hz, 1H), 3.70 (d, J = 14.0 Hz, 1H) (part of AB
system), 3.62 (d, J = 18.5 Hz, 1H), 3.54 (d, J = 14.0 Hz, 1H) (part of
AB system) ppm. 13C NMR (101 MHz, DMSO-d6): δ = 171.1, 164.2,
162.2, 161.1, 155.3, 144.3, 135.8, 129.6, 129.1 (2C), 128.3 (2C), 126.6,
112.8 (2C), 101.6, 67.5, 66.3, 58.3, 45.3, 41.5 ppm. LRMS: mass calcd
for C25H19N2O8S (M − H) 507.09, mass found (M − H) 507.0.
Retention time: 7.15 min (purity 99%).
(6R,7R)-8-Oxo-3-(((2-oxo-2H-chromen-7-yl)oxy)methyl)-7-(2-
phenylacetamido)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-car-
boxylic Acid 5,5-Dioxide (FC5). Compound 6 (20 mg, 0.03 mmol)
was cooled to 0 °C prior to the addition of TFA/anisole (5:1, 1.2 mL).
The reaction was stirred at 0 °C for 30 min followed by 30 min at rt
with constant monitoring of the conversion by TLC analysis (CH2Cl2/
MeOH, 9:1). Upon completion of the reaction, cold Et2O (5 mL) was
added, which resulted in the formation of a precipitate. The solid
material was ﬁltered oﬀ, washed with Et2O (2 × 3 mL), and
subsequently dried under high vacuum to yield the desired product as
an oﬀ-white solid (10 mg, 63%). Rf = 0.10 (CH2Cl2/MeOH +AcOH,
9:1). 1H NMR (400 MHz, DMSO-d6): δ = 8.92 (d, J = 9.0 Hz, 1H),
8.01 (d, J = 9.5 Hz, 1H), 7.66 (d, J = 8.5 Hz, 1H), 7.19−7.31 (m, 5H)
7.04 (d, J = 2.5 Hz, 1H), 6.99 (dd, J = 8.5, 2.5 Hz, 1H), 6.32 (d, J = 9.5
Hz, 1H), 5.97 (dd, J = 8.5, 4.5 Hz, 1H), 5.42 (d, J = 4.5 Hz, 1H),
4.90−5.00 (m, app q, 2H), 4.41 (d, J = 18.0 Hz, 1H), 4.19 (d, J = 18.0
Hz, 1H), 3.54−3.65 (m, app q, 2H) ppm. 13C NMR (101 MHz,
DMSO-d6): δ = 170.9, 164.3, 162.1, 160.8, 160.2, 155.2, 144.3, 135.6,
129.6, 129.2 (2C), 128.2 (2C), 126.5, 125.2, 123.8, 112.9, 112.9, 101.7,
66.8, 66.3, 58.3, 50.8, 41.2 ppm. LRMS: mass calcd for C25H19N2O8S
(M − H) 507.09, mass found (M − H) 507.0. Retention time: 8.98
min (purity 95%).
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